Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and tolerability and determine the
pharmacokinetics of subcutaneous single and multiple (up to 12) dose administration of
CBX129801 (long-acting synthetic C-peptide) in type 1 diabetes patients.